https://www.clinicalobserver.com/policy/fda-approves-first-factor-xia-inhibitor-to-prevent-recurrent-strokeClinical Observeren2026-11-09T22:58:00.485ZFDA approves Sunharbo as first factor XIa inhibitor after strokehttps://www.clinicalobserver.com/public-health/measles-exposure-possible-at-toronto-pearson-after-child-caseClinical Observeren2026-11-09T22:07:27.466ZMeasles exposure possible at Toronto Pearson after child casehttps://www.clinicalobserver.com/biotech/survodutide-passes-cardiovascular-safety-test-in-phase-3-obesity-trialClinical Observeren2026-11-09T19:11:08.807ZSurvodutide passes cardiovascular safety test in Phase 3 obesity trialhttps://www.clinicalobserver.com/biotech/gene-therapy-cancer-risk-materializes-in-pediatric-casesClinical Observeren2026-11-09T17:35:21.897ZGene therapy cancer risk materializes in pediatric caseshttps://www.clinicalobserver.com/policy/fda-requires-glp-1-drug-labels-to-warn-of-rare-eye-conditionClinical Observeren2026-11-09T16:17:51.685ZFDA requires GLP-1 drug labels to warn of rare eye conditionhttps://www.clinicalobserver.com/biotech/capricors-hope-3-cardiac-results-for-deramiocel-win-aha-awardClinical Observeren2026-11-09T15:14:25.292ZCapricor's HOPE-3 cardiac results for Deramiocel win AHA awardhttps://www.clinicalobserver.com/policy/cms-publishes-final-medicare-drug-negotiation-ruleClinical Observeren2026-11-08T16:07:44.547ZCMS publishes final Medicare drug negotiation rulehttps://www.clinicalobserver.com/public-health/warren-demands-answers-from-kennedy-over-cyclosporiasis-outbreakClinical Observeren2026-11-08T13:12:01.491ZWarren demands answers from Kennedy over cyclosporiasis outbreak